Pure Global AI
NCT06230562Not yet recruiting

DIAGALS: Relation Between Tar DNA Binding Protein(TDP)-43 et Nrf-2 in ALS: a Track to Improve Diagnosis and Prognosis of the Disease

DIAGALS: Relation Between TDP-43 et Nrf-2 in ALS: a Track to Improve Diagnosis and Prognosis of the Disease: Prospective, Bicentric, Non-randomized, Open-label Study
University Hospital, ToursClinicalTrials.govbiological
Study focus
Drug/Device/Intervention
Blood sample
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
University Hospital, Tours
Timeline & enrollment
Phase
N/A
Start date
Feb 01, 2024
End date
Aug 01, 2025
Enrollment
60 participants
Primary outcome

Presence of TDP-43 aggregates in PBMC,PBMC accompanied by a protein expression profile under Nrf-2 control

Summary

In response to oxidative stress, cells activate the Nrf-2 pathway, which induces translation
 of its target genes and corresponding proteins involved in the antioxidant response. This
 explains the interest in the Nrf-2 pathway in the pathophysiology of Amyotrophic lateral
 sclerosis (ALS), supported by the results of several studies and the modulatory effect of
 TDP-43 on the Nrf-2 pathway. Since both TDP-43 and Nrf-2 proteins are present in the
 peripheral blood mononuclear cells (PBMC) of ALS patients and may be correlated with disease
 progression, the investigators wish to explore their relationship and their application in
 the clinic as potential blood biomarkers for ALS.

ICD-10 classifications
Neuralgic amyotrophyMotor neuron diseaseOther degenerative diseases of the nervous systemOther degenerative disorders of nervous system in diseases classified elsewhereMultiple sclerosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06230562
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06230562 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital, Tours and is currently Not yet recruiting. The study focuses on Amyotrophic Lateral Sclerosis. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.